Categories: BrainNews

NeuroOne® to Report Fourth Quarter and Fiscal Year 2024 Financial Results on December 17 at 9:00 a.m. Eastern Time

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

EDEN PRAIRIE, Minn., Dec. 04, 2024 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for the fiscal fourth quarter and year ended September 30, 2024, before market open on December 17, 2024.

Management will host an investor conference call and webcast at 9:00 a.m. Eastern time on Tuesday, December 17, 2024 to discuss the Company’s fourth quarter and fiscal year 2024 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the following infomaiton:

Fourth Quarter and Fiscal 2024 Earnings Conference Call
Date: Tuesday, December 17, 2024
Time: 9:00 a.m. Eastern time
U.S. Dial-In (Toll Free): 888-506-0062
International Dial-In: 973-528-0011
Participant Access Code: 603219
Webcast: NMTC Fourth Quarter and Fiscal 2024 Earnings Conference Call

Please join at least five minutes before the start of the call to ensure timely participation.

A playback of the call will be available through December 31, 2024. To listen, please call 877-481-4010 within the United States or 919-882-2331 when calling internationally, using replay passcode 51728. A webcast replay will also be available using the webcast link above through December 17, 2025.

About NeuroOne

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit www.nmtc1.com.

IR Contact
MZ Group – MZ North America
NMTC@mzgroup.us

Staff

Recent Posts

NeuroOne Medical Technologies Corporation Announces Pricing of $8.0 Million Public Offering of Common Stock

EDEN PRAIRIE, Minn., April 04, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC)…

1 hour ago

Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025

Three epilepsy posters to be presented in scientific sessions at the American Academy of Neurology…

1 hour ago

Entourage Health Corp. Announces Closing of Plan of Arrangement

TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) (FSE:…

1 hour ago

Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease

SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced “Trix”), a clinical-stage biopharmaceutical…

1 hour ago

Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee

Highly experienced biotech executive and board member will assist Kalaris in achieving its next phase…

1 hour ago

AIM Congress 2025 Kicks Off in Abu Dhabi on Monday with 20,000 Participants

 Al Zeyoudi: "Hosting such major international events reflects the UAE's pivotal role as a global…

4 hours ago